Area of research
Oncology · Cancer Research
Research interest
Research interests include HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, and Cancer Treatment and Pharmacology.
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early <i>ERBB2</i>-Positive Breast Cancer
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
Reply to M. Kusumoto et al.
Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma.
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
Children and adolescents with ADHD followed up to adulthood: a systematic review of long-term outcomes.
LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Early versus delayed palliative/supportive care in advanced cancer: an observational study.
<i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS)
Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device).
New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials.
Worse global intellectual and worse neuropsychological functioning in preterm-born children at preschool age: a meta-analysis.
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
Stereotactic Ablative Radiotherapy as an Alternative to Lobectomy in Patients With Medically Operable Stage I NSCLC: A Retrospective, Multicenter Analysis.
Direct oral anticoagulants vs non-vitamin K antagonist in atrial fibrillation: A prospective, propensity score adjusted cohort study.
Usefulness of automated breast volume scanner (ABVS) for monitoring tumor response to neoadjuvant treatment in breast cancer patients: preliminary results.
PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.
Heated tobacco and politics in Italy.
Selenium for preventing cancer
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
Rapamycin treatment for amyotrophic lateral sclerosis
Use of adjunct cardiovascular therapy in patients hospitalised for acute exacerbations of COPD